Ocular Therapeutix Inc
NASDAQGM:OCUL
United States / Healthcare / Pharmaceuticals
OCUL News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, Ocular), a biopharmaceutical company committed to redefining the retina experience,...
Ocular Therapeutix Inc receives Investment Bank Analyst Rating Update
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI
On Monday, 10 March 2025, Ocular Therapeutix (NASDAQ: OCUL) presented at the Leerink Global Healthcare Conference 2025, offering a strategic overview of its lead product candidate,...
Ocular Therapeutix Inc receives Investment Bank Analyst Rating Update
Ocular Therapeutix announce inducement grants to new employee
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one...
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, Ocular), a biopharmaceutical company committed to redefining the retina experience,...
H.C. Wainwright maintains $15 target on OCUL stock with Buy rating
On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $15.00 price target for Ocular Therapeutix (NASDAQ:OCUL), following the company's latest financial results and updates on...
Ocular Therapeutix Inc receives Investment Bank Analyst Rating Update
JMP cuts OCUL stock target to $19 but keeps positive outlook
On Tuesday, JMP Securities adjusted its financial outlook for Ocular Therapeutix (NASDAQ:OCUL), reducing the price target from $22.00 to $19.00 while reaffirming a Market...